PIK3CA and breast cancer: Attempts to enhance the G1/S arrest action are currently under clinical investigation, e.g., based on a concurrent PI3K-pathway inhibition for breast cancer (triple therapy), or a sequential use of these agents in cases bearing PIK3CA mutations [8].